Article
Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab.
The Journal of clinical endocrinology and metabolism - 1 Oct 2018
Lin Andrew L, Jonsson Philip, Tabar Viviane, Yang T Jonathan, Cuaron John, Beal Katherine, Cohen Marc, Postow Michael, Rosenblum Marc, Shia Jinru, DeAngelis Lisa M, Taylor Barry S, Young Robert J, Geer Eliza B
Abstract excerpt
Context: Pituitary carcinoma is a rare and aggressive malignancy with a poor prognosis and few effective treatment options. Case: A 35-year-old woman presented with an aggressive ACTH-secreting pituitary adenoma that initially responded to concurrent temozolomide and capecitabine prior to metastasizing to the liver. Following treatment with ipilimumab and nivolumab, the tumor volume of the dominant liver...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.